One size does not fit all: PMRT in ypN0 HER-2 positive breast cancer

We thank Merdan Fayda for his interest[ [1] Fayda M. Having ypN0 may not be enough to abandon the postmastectomy radiotherapy (PMRT) in Her-2 positive patients [Letter to The Editor]. Radiother Oncol. 2023; Google Scholar ] in our recent work evaluating the role of PMRT in HER-2 positive breast cancer patients[ [2] Saifi O. Bachir B. Panoff J. Poortmans P. Zeidan Y.H. Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: Pooled analysis of TRYPHAENA and NeoSphere trials. Radiother Oncol. 2023; 184109668 Abstract Full Text Full Text PDF Scopus (0) Google Scholar ]. Most of the raised comments are echoed in the limitations section within the discussion section of our article. Such limitations are common within the context of a secondary analysis. However, there are few points that are worth clarifying.